2 recruiting, 1 active not recruiting, 1 completed. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow endocrine therapy: new trials by email Literature Review of endocrine therapy trials Research Report on endocrine therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure entinostat, Pyrotinib, endocrine therapy - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 94 | 2025-06-23 | 2026-07-16 |
| SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy - Brain Metastases, HR+ Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 31 | 2021-11-30 | 2026-09-28 |
| A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body LY3295668 Erbumine, Endocrine therapy, Midazolam - Metastatic Breast Cancer | Phase 1 | Completed | Eli Lilly and Company | 5 | 2019-08-02 | 2020-06-01 |
| A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread LY2835219, Letrozole, Anastrozole - Breast Neoplasms | Phase 1 | Active not recruiting | Eli Lilly and Company | 198 | 2014-03-10 | 2026-01-26 |
Breast Neoplasms (3) · Brain Neoplasms (1) · Epilepsy (1)
Eli Lilly and Company (2) · H. Lee Moffitt Cancer Center and Research Institute (1) · Tianjin Medical University Cancer Institute and Hospital (1)
United States (3) · Belgium (1) · China (1)
Heather Han, MD (1) · Kamran A Ahmed, MD (1)
2018 (1)